Avacta’s AffiDX® SARS-CoV-2 lateral flow test detects both B117 ‘Kent’ and D614G variants of the virus
Avacta’s AffiDX® SARS-CoV-2 lateral flow test detects both B117 ‘Kent’ and D614G variants of the virus
The Company is a newly established investing company, seeking to provide investors with exposure to a portfolio concentrating on fast-growing and/or high potential Life Sciences businesses operating predominantly in the
Collaboration with Integumen plc for Detection of SARS-COV-2 Coronavirus in Waste Water